Committed to Scientific Excellence

Our discoveries have led to the development of new treatments that have improved patients' lives worldwide. Since the 1950s, we have discovered and introduced several novel antibiotics.

While other companies have abandoned antibiotic drug development over the past decade, we have continued to explore and remain committed to developing antibiotic drugs. Our R&D story extends beyond antibiotics to include novel medications for HIV and influenza.
Through in-house discovery and strategic partnerships, we are delivering firsts for patients in the U.S. and around the world. As part of the Global Health Innovative Technology Fund, our scientists work with strategic partners to research therapies for treating patients with multi-drug-resistant tuberculosis, neglected tropical diseases, and more.

  • In the U.S., our R&D efforts are focused on developing an investigational oral antiviral for COVID-19 and advancing clinical programs in Fragile X syndrome, acute ischemic stroke, metabolic disorders and oncology.

    Pipeline

  • As part of our commitment to addressing unmet medical needs, Shionogi and collaborating organizations are currently enrolling or preparing to enroll participants in clinical trials for infectious diseases, neurology/CNS, metabolic disorders and oncology.

    Clinical Trials

  • Our commitment to scientific innovation includes supporting investigator-initiated research.

    Investigator Research

  • We provide CME medical education grants focusing on Gram-negative infections.

    Educational Grants

  • We believe that disclosing detailed information about clinical trials advances scientific progress, improves public health, and ultimately helps patients and healthcare providers make informed clinical decisions.

    Clinical Trial Policy

  • Shionogi supports healthcare providers in publishing research on Gram-negative multidrug-resistant infections by providing grants for medical writing support and grants through independent agencies.

    Medical Writing Grants

  • We provide current, accurate and evidenced-based information to help healthcare professionals make informed decisions about the safe and appropriate use of our products.

    Medical Information

  • Shionogi may be able to supply an investigational drug for qualified patients with a serious disease and when alternative therapy and a clinical trial are not options.

    Expanded Access Policy

Our Products

With our deep legacy in research and development, we have a proven track record of bringing innovative medicines from our labs to patients.
Learn More about Our Products

Partnering to Bring Meaningful Science to Patients

We collaborate with industry partners, government agencies and early-stage biotechs that are focused on advancing science with the urgency that today's global health challenges demand.
Partner with Us

Join Our Team

We are driven to impact patient lives and bring better solutions to the communities we serve. We are bold, curious, and excited by the opportunity to be part of something big. If that sounds like you, Shionogi may be the place where you can make your mark.
Discover Our Career Opportunities